GlassScriptPhysician profile
Maxim Bitunov
NPI 1821430349
$2,813.05
in general payments reported to CMS, 2019-2025
16 companies · $894 in 2025
The $894 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $12.64 · 2021: $315 · 2022: $831 · 2023: $204 · 2024: $299 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $520.34 | 2022-2025 | Kisunla, Zepbound, Mounjaro |
| Abbvie INC. | $406.50 | 2022-2025 | Qulipta |
| Glaxosmithkline, LLC. | $301.86 | 2021-2025 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $190.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $184.23 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.62 | 2022-2025 | Caplyta |
| Abbott Laboratories | $133.63 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.86 | 2019 | |
| Neurocrine Biosciences, INC. | $124.55 | 2025 | |
| Verona Pharma, INC. | $123.64 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $120.65 | 2023 | Veozah |
| Gilead Sciences, INC. | $112.64 | 2020-2022 | |
| Amgen INC. | $109.14 | 2024 | Evenity |
| Axsome Therapeutics, INC. | $95.00 | 2024 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $92.45 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Bitunov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.